Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:

Slides:



Advertisements
Similar presentations
Workshop C – Evaluation Rod Taylor Complex Interventions Research Framework Masterclass 2010.
Advertisements

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlikeLicense. Your use of this material constitutes acceptance of that license.
ECONOMIC EVALUATION WHY DO YOU NEED TO BOTHER? JUDITH BOSMANS.
Correcting Market Distortions: Shadow Prices, Shadow Wages and Discount Rates Chapter 6.
1 Are you sure your improvements are cost-effective? Edward Broughton, PhD, MPH, PT University Research Co. April 11, 2014
Cost-Effectiveness Using Decision-Analytic Models
Alternative antiretroviral monitoring strategies for HIV-infected patients in resource-limited settings: Opportunities to save more lives? R Scott Braithwaite,
Economic Analysis and Management Todd Wagner, PhD.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. February 25, 2009.
Costs and Cost Effectiveness HINF Medical Methodologies Session 15.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
317_L25, Mar J. Schaafsma 1 Review of the Last Lecture Have discussed three methods for shadow pricing life and limb for CBA: human capital method,
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
Presenter: Joseph Reid Paper: The Market for Health Care Date : 6/04/07.
Schneider Institute for Health Policy Heller School Brandeis University September Donald S. Shepard, Ph.D. Schneider Institute for Health Policy.
Cost-effectiveness Analysis: A practical primer Eran Bendavid.
The Panel on Cost-Effectiveness in Health and Medicine Marthe Gold City University of London 30 October, 2003.
Investment, the Capital Market, and the Wealth of Nations
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
1 Cost-Utility Analysis Cost-Effectiveness Analysis Scott Matthews Courses: / / Lecture /9/2005.
Engineering Systems Analysis Richard de Neufville © Massachusetts Institute of Technology Economic Evaluation Slide 1 of 22 Economic Evaluation l Objective.
Drug and Therapeutics Committee
Chapter 4: Economic Efficiency and Cost Benefit Analysis 1.Economic Efficiency 2.Cost Benefit Analysis.
Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
Cost Effectiveness Analysis To Enhance Mammography Use Dave Alvey Paul Moley.
Benefit/Cost Analysis Lecture slides to accompany
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
1 Econoqualimetrics Edward Broughton, PhD., MPH Senior Economic Analyst, USAID Health Care Improvement Project, EnCompass,
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 1: Introduction Sept 3, 2008.
Lecture 3 Economic Efficiency and Cost Benefit Analysis Tianxu Chen
Weissert 1 Cost-Benefit, Cost-Effectiveness Analysis, and An Application to Home Care William Weissert Professor and Chair Department of Health Management.
Outcomes based approach to measuring the impact of new technology Vikas Arya HSCI 740 Spring 2004 May 22,2004.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
What cost evidence supports the use of technologies in home and community based caregiving of older adults? Presented by Brooke Harrow, PhD University.
Monetary Policy Review
Cost-Effectiveness Thresholds Professor of Health Economics
Economic evaluation Definition - the comparative analysis of alternative courses of action in terms of both their cost and consequences.
Health Economics Unit Definition of Economics  Demand − relationship between quantities and prices that addresses how much bought at each price.
Cost-effectiveness Analysis: Overview & Developing an analysis Training in Clinical Research DCEA Lecture 3 UCSF Department of Epidemiology and Biostatistics.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Cost-effectiveness Analysis: Overview; Developing an analysis Advanced Training in Clinical Research DCEA Lecture 3 UCSF Department of Epidemiology and.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. September 14, 2011.
Chapter 4: Cost-Benefit Analysis Chapter 4 Cost-Benefit Analysis Copyright © 2009 by The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin.
© 2012 by McGraw-Hill All Rights Reserved 9-1 Lecture slides to accompany Engineering Economy 7 th edition Leland Blank Anthony Tarquin Chapter 9 Benefit/Cost.
1 Responding to the Challenge of Rising Health Care Costs: Employer and Health Plan Strategies Health Policy Audio Conference Robert S. Galvin, MD July.
WHAT IS HEALTH ECONOMICS? ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ PHYSICIANS CARE ONLY ABOUT PATIENTS…… PHYSICIANS.
Chapter 5 ELEMENTS OF DEMAND AND CONSUMER CHOICE.
Flagship Program on Health Sector Reform and Sustainable Financing.
Introduction to Economics of Water Resources. Public or private Excludability (E): the degree to which users can be excluded Subtractability (S): the.
Utility- is the satisfaction you receive from consuming a good or service Total utility is the number of units of utility that a consumer gains from consuming.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Health Policy Analysis: Chapters 10, 11 and 14 Nutchanart Bunthumporn Beth Faiman.
Cost and Benefits. Introduction Is treatment X worth it?
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
CRJS 4466 PROGRAM & POLICY EVALUATION LECTURE #6 Evaluation projects Questions?
1 Is it cost-effective to kill patients? Edward Broughton, PhD., MPH Director, USAID Health Care Improvement Project, University Research Co.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 7: Cost-effectiveness analysis – Part.
1 Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID Health Care Improvement Project, University Research Co., LLC
Chapter 14 Economic Analysis of Clinical and Managerial Interventions Copyright 2015 Health Administration Press.
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
Economic Evaluation of Health Interventions Basic Concepts
Assessing value for money: principles, methods and issues
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:

Issue: Limited Resources l Assumption: There’s not enough money to fund every effective treatment (screening program, etc.) l Goal: Get the most health for our money. How can we allocate our fixed budget to provide the most health care?

Answer: Cost-Effectiveness l Determine how much health per dollar each intervention provides - its “cost- effectiveness” and how many of these interventions are needed l Fund interventions in decreasing order of cost-effectiveness until the budget is spent.

Cost-effectiveness l Fund I,B,G,E,C,D, and H for 291 patients: 15,374.8 HBUs (3.06 per 5031 people)

Effectiveness only l Result: Fund A-D and E for 1498 patients: 13,994.2 HBUs (3.21 per 4338 people)

Perspective l Patient perspective l Cost to patient (may be 0 due to insurance) l Health to patient l Payer’s perspective l Cost to payer (employer, HMO, insurance) l Health to patient pool l Social perspective l Cost to society, including lost productivity l Health to society

Measuring Costs l Costs are usually measured in dollars, adjusted for inflation over time. l Costs differ from charges, which include profits, market effects, etc. l Costs should include future related medical costs and savings. Future costs are discounted

Future Costs l Some argue that costs should include all future costs and savings (wages, etc.) If you do this: l Life-extending interventions become less cost- effective than life-enhancing interventions, because you’re usually extending low-quality life. l Life-saving interventions become less cost- effective in the elderly, who are net consumers, than in the young, who are net producers.

Benefit, Effectiveness, Utility l Cost-benefit analysis: Benefit in dollar units (e.g. willingness to pay for result) l Cost-effectiveness analysis: Benefit in health units (e.g. AIDS cases prevented, lives saved) l Cost-utility analysis: Benefit in utility (quality-of-life) units (e.g. QALYs)

Measuring Effectiveness l The recommended measure for cost- effectiveness is the quality-adjusted life year, a common unit for comparison. l QALYs =  (time in state * utility of state) l 1 year of life in perfect health is as good as 2 years of life in 0.5 utility health. l Under $50,000 or $100,000/QALY is widely regarded as “cost-effective”

Graphing the CE Ratio

CEA problem 2 From Stinnett & Paltiel’s CEA short course You must choose which of 5 mutually exclusive programs to fund. You currently fund option A. Considering your other decisions, you’re willing to spend up to an additional $200,000 per QALY.

Marginal CEA (aka Incremental CEA) l What if we have to weigh programs against each other, or determine if a new treatment is better to give than the current standard? l Marginal CEA focuses on how much more health could we get by spending an additional amount

CEA Problem 2 Step 1: Order the programs by cost. If some option costs more and delivers less than another, eliminate it from consideration.

CEA Problem 2 Step 2: Calculate a marginal CE ratio for each program, relative to the one above it.

CEA Problem 2 Step 3: Eliminate any program that has a higher marginal CE ratio than the program below it. If you’d spend $571k more to get 17.1 more QALYs, instead spend $175k more to get 17.9.

CEA Problem 2 Step 4: Recalculate marginal CE ratios and choose the program that has the largest marginal CE ratio that’s less than the threshold CE ratio ($200,000). In this case, neither C nor E meets our threshold. We should continue to fund A.

CEA Guidelines The Panel on Cost-Effectiveness in Health and Medicine (1993) 1. Reference case analysis l Societal perspective (resource allocation) l Compare interventions with status quo l Use QALYs; based utilities on community preferences, not patient preferences l Use direct and indirect costs, but need not include unrelated future health and non- health costs. Discount costs at 3%. 2. Perform sensitivity analysis

Conclusions l Cost-effectiveness analysis asks how to spend a fixed budget for the most health l The cost-effectiveness of an intervention is usually reported as its cost-per-QALY ratio. l Interventions with lower $/QALY are more cost-effective and should be preferred to interventions with higher $/QALY